Middle East Pharmaceutical Industries Company SJSC
SAU:4016
Middle East Pharmaceutical Industries Company SJSC
Revenue
Middle East Pharmaceutical Industries Company SJSC
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
M
|
Middle East Pharmaceutical Industries Company SJSC
SAU:4016
|
Revenue
ď·Ľ338.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Saudi Pharmaceutical Industries and Medical Appliances Corporation SJSC
SAU:2070
|
Revenue
ď·Ľ1.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
1%
|
|
J
|
Jamjoom Pharmaceuticals Factory Company SJSC
SAU:4015
|
Revenue
ď·Ľ1.3B
|
CAGR 3-Years
21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Middle East Pharmaceutical Industries Company SJSC
Glance View
Middle East Pharmaceutical Industries Company SJSC is a SA-based company operating in Pharmaceuticals industry. The company is headquartered in Riyadh, Riyadh and currently employs 335 full-time employees. The company went IPO on 2024-02-27. Middle East Pharmaceutical Industries Company SJSC is a Saudi Arabia-based pharmaceutical company. The firm develops, manufactures, markets, and distributes a wide range of generic medicines and pharmaceuticals. The Company’s activity is the manufacture of disinfectants and sterilizers for medical devices and products, the manufacture of disinfectants and sterilizers for non-medical use, the manufacture of cosmetics, and the manufacture of pharmaceutical preparations for human use.
See Also
What is Middle East Pharmaceutical Industries Company SJSC's Revenue?
Revenue
338.4m
SAR
Based on the financial report for Dec 31, 2023, Middle East Pharmaceutical Industries Company SJSC's Revenue amounts to 338.4m SAR.
What is Middle East Pharmaceutical Industries Company SJSC's Revenue growth rate?
Revenue CAGR 3Y
4%
Over the last year, the Revenue growth was 12%. The average annual Revenue growth rates for Middle East Pharmaceutical Industries Company SJSC have been 4% over the past three years .